Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high‐risk Langerhans cell histiocytosis

Documenti analoghi

• Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib
  di: Irene Trambusti, et al.
  Pubblicazione: (2024)
• Diagnostic impact of exome sequencing in haemophagocytic lymphohistiocytosis: A report from the Italian reference centre
  di: Aurora Chinnici, et al.
  Pubblicazione: (2025)
• Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
  di: Deevyashali Parekh, et al.
  Pubblicazione: (2024)
• From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies
  di: Akiva Diamond
  Pubblicazione: (2024)
• Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia
  di: Benjamin J. Lee, et al.
  Pubblicazione: (2025)